Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6472
-0.0291-4.30%
Post-market: 0.65480.0076+1.17%19:50 EDT
Volume:11.50M
Turnover:7.65M
Market Cap:157.27M
PE:-0.87
High:0.7060
Open:0.6759
Low:0.6400
Close:0.6763
52wk High:3.39
52wk Low:0.1611
Shares:243.00M
Float Shares:214.26M
Volume Ratio:0.22
T/O Rate:5.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-184.82%
PB:-5.42
PE(LYR):-0.36

Loading ...

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

TIPRANKS
·
Apr 22

Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31

Reuters
·
Apr 22

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Apr 22

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

TIPRANKS
·
Apr 22

BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)

Reuters
·
Apr 21

Outlook Therapeutics Inc - Expects FDA Feedback in May 2026

THOMSON REUTERS
·
Apr 21

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Benzinga_recent_news
·
Apr 08

Outlook Therapeutics submits formal dispute resolution request to FDA

TIPRANKS
·
Apr 07

BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision

Reuters
·
Apr 07

BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA

Reuters
·
Apr 07

Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds

Reuters
·
Mar 26

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Dow Jones
·
Mar 26

Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced

MT Newswires Live
·
Mar 25

Outlook Therapeutics prices USD 5 million public offering at USD 0.25 per share with warrants

Reuters
·
Mar 24

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

THOMSON REUTERS
·
Mar 24

BRIEF-Outlook Therapeutics Announces Proposed Public Offering

Reuters
·
Mar 24

Outlook Therapeutics launches best-efforts public offering of common stock and warrants

Reuters
·
Mar 24

Outlook Therapeutics Launches LYTENAVA in Germany and the UK

Reuters
·
Mar 24

Outlook Therapeutics Inc - Extends Maturity Date of Existing Convertible Note to December 31, 2026

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Enters $18.4 Mln New Note, Expects $17 Mln Net Proceeds

THOMSON REUTERS
·
Mar 16